SOUTH SAN FRANCISCO, CA, Presidio Medical, a clinical-stage medical device company, announced the close of a $72 million Series C funding round led by Deerfield Management.
Presidio Medical, Inc., a clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, announced the close of a $72 million Series C funding round led by Deerfield Management, existing investors Invus Opportunities and Action Potential Venture Capital, and joined by ShangBay Capital. Proceeds will be used to expand the team, scale manufacturing, and conduct long-term, pivotal clinical studies of Presidio's unique ULF™ SCS system.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
